Concepedia

Kenichi Umehara

KU

Statistics

Publications

31

Citations

964

H-Index

20

Active since

1998

Affiliations

Novartis (Switzerland)(Current)

Roche (Switzerland)

Novartis Institutes for BioMedical Research

Novartis (United States)

Astellas Pharma (Japan)

Kenichi Umehara is an author at Novartis (Switzerland) specializing in pharmacology, pharmacokinetics, and pharmacy.

ORCID

Publications per year

1998–2023

31

Publications

31

Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: <i>In Silico</i> and Clinical Evaluations

Tanay S. Samant, Shyeilla V. Dhuria, Yasong Lu et al. · Clinical Pharmacology & Therapeutics · 2017 · 81 citations · Full text

, , +16

Predicting human hepatic clearance from<i>in vitro</i>drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug–drug interactions

Gian Camenisch, Kenichi Umehara · Biopharmaceutics & Drug Disposition · 2012 · 76 citations

, , +17

Novel In Vitro-In Vivo Extrapolation (IVIVE) Method to Predict Hepatic Organ Clearance in Rat

Kenichi Umehara, Gian Camenisch · Pharmaceutical Research · 2011 · 65 citations

, , +14

Functional involvement of organic cation transporter1 (OCT1/Oct1) in the hepatic uptake of organic cations in humans and rats

Kenichi Umehara, Takeshi Iwatsubo, K. Noguchi et al. · Xenobiotica · 2007 · 60 citations

, , +17

Characterization of Human Organic Cation Transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-Mediated Transport of 1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium Bromide (YM155 Monobromide), a Novel Small Molecule Survivin Suppressant

Tsuyoshi Minematsu, Megumi Iwai, Kenichi Umehara et al. · Drug Metabolism and Disposition · 2009 · 57 citations

, , +10

1–5 of 31